Aztreonam
Brand Names: Azactam, Cayston
Methodology & AI Transparency ⓘ
Aztreonam Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
- 2 Real-world patient consensus: Tracked across 18 patient dosage logs with a 82% satisfaction benchmark (RxCUI 1664981).
- 3 Typical cash cost range: 30-day cash pricing ranges from $95.98 discount cash to $235.15 walk-in retail (NADAC $2.1600/unit).
- 4 Top reported side effects / signs: Most commonly reported Aztreonam tolerability events: nausea (11.6%), diarrhea (8.9%), vomiting (5.2%).
Ask our AI Specialists anything about Aztreonam
Aztreonam Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
CLINICAL PHARMACOLOGY Single 30-minute intravenous infusions of 500 mg, 1 g, and 2 g doses of AZACTAM in healthy subjects produced aztreonam peak serum levels of 54 mcg/mL, 90 mcg/mL, and 204 mcg/mL, respectively, immediately after administration; at 8 hours, serum levels were 1 mcg/mL, 3 mcg/mL, and 6 mcg/mL, respectively ( Single 3-minute intravenous injections of the same doses resulted in serum levels of 58 mcg/mL, 125 mcg/mL, and 242 mcg/mL at 5 minutes following completion of injection.
Systemic exposure to Aztreonam reflects Complete (~100%) parenteral systemic delivery for Aztreonam (2 g/1 Injection, Powder, Lyophilized, for Solution) absorption kinetics and hepatic enzymatic processing and renal clearance proportional to creatinine clearance (aztreonam), sustaining receptor engagement across a Biphasic clearance with 11–17 hr terminal t½ under Aztreonam maintenance half-life window (rapid intravascular/parenteral onset within 15–45 minutes after aztreonam administration response profile).
Dosing protocols (2 g/1 Injection, Powder, Lyophilized, for Solution or 1 g/1 Injection, Powder, for Solution or 1 g/1 Injection, Powder, Lyophilized, for Solution or 2 g/1 Injection, Powder, for Solution or Kit) balance efficacy (82.00% patient satisfaction across 18 logs) against nausea (11.6% of reports), diarrhea (8.9% of reports), headache (5.7% of reports), with strict avoidance in contraindications this preparation is contraindicated in patients with known hypersensitivity to aztreonam or any other component in the formulation.; severe drug-induced hypersensitivity to aztreonam or inactive tablet/vehicle binders.
Assess baseline hepatic panels and interacting prescriptions when starting Aztreonam (monobactam antibacterial).
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Aztreonam dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS This preparation is contraindicated in patients with known hypersensitivity to aztreonam or any other component in the formulation.
- Severe drug-induced hypersensitivity to Aztreonam or inactive tablet/vehicle binders
Logged Side-Effect Incidence (18 Reports)
Aztreonam Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Aztreonam)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute: What a 335-Participant Study Found TARGET demonstrated that ceftobiprole is noninferior to vancomycin/aztreonam in the treatment of ABSSSIs, in terms of early clinical response and investigator-assessed clinical success at the TOC visit. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2021-10-05 • Phase III Randomized Trial | N = 335 | 93/100 | PMID 32897367 ↗ |
Aztreonam Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.1600/unit (~$64.80/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $235.15 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $95.98 / mo | View logs ↓ |
Aztreonam Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Aztreonam RxNorm Concept ID | 1664981 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.1600 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $235.15 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $95.98 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 82.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Aztreonam Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Aztreonam integrating DailyMed SPL (2025-12-15), CMS NADAC ($2.1600/unit), and 18 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Aztreonam community threads and patient logs by age, biological sex, dosage, and treatment duration.